Meta Health (SGX:5DX) has amended its acquisition agreement for a 55% stake in Jas Medical Screening Centre, adjusting the terms for performance-based earn-out shares and contingent introducer shares, according to a Thursday filing on the Singapore Exchange.
Under the revised terms, shares will be issued if Jas Medical achieves net profits of at least SG$175,000 in 2025 and 2026, with adjustments linked to changes in Meta's share base.
Independent reviewers will verify the calculations. The company clarified that these amendments do not alter the deal's structure.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。